These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 35866733)

  • 1. Clinical-functional characterization of patients with spinal muscular atrophy in Central-Western Colombia.
    Cardona N; Ocampo SJ; Estrada JM; Mojica MI; Porras GL
    Biomedica; 2022 May; 42(Sp. 1):89-99. PubMed ID: 35866733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and radiological profile of patients with spinal muscular atrophy type 4.
    Souza PVS; Pinto WBVR; Ricarte A; Badia BML; Seneor DD; Teixeira DT; Caetano L; Gonçalves EA; Chieia MAT; Farias IB; Bertini E; Oliveira ASB
    Eur J Neurol; 2021 Feb; 28(2):609-619. PubMed ID: 33090613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nusinersen treatment of Spinal Muscular Atrophy Type 1 - results of expanded access programme in Poland.
    Modrzejewska S; Kotulska K; Kopyta I; Grędowska E; Emich-Widera E; Tomaszek K; Paprocka J; Chmielewski D; Pilch J; Pietruszewski J; Lemska A; Zawadzka M; Mazurkiewicz-Bełdzińska M
    Neurol Neurochir Pol; 2021; 55(3):289-294. PubMed ID: 33565602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Muscle strength and motor function throughout life in a cross-sectional cohort of 180 patients with spinal muscular atrophy types 1c-4.
    Wadman RI; Wijngaarde CA; Stam M; Bartels B; Otto LAM; Lemmink HH; Schoenmakers MAGC; Cuppen I; van den Berg LH; van der Pol WL
    Eur J Neurol; 2018 Mar; 25(3):512-518. PubMed ID: 29194869
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Responsiveness of the motor function measure in patients with spinal muscular atrophy.
    Vuillerot C; Payan C; Iwaz J; Ecochard R; Bérard C;
    Arch Phys Med Rehabil; 2013 Aug; 94(8):1555-61. PubMed ID: 23380348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Motor unit number index (MUNIX) in children and adults with 5q-spinal muscular atrophy: Variability and clinical correlations.
    Mendonça RH; Machado LMS; Heise CO; Polido GJ; Matsui C; Silva AMS; Reed UC; Zanoteli E
    Neuromuscul Disord; 2021 Jun; 31(6):498-504. PubMed ID: 33824074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Executive function is inversely correlated with physical function: the cognitive profile of adult Spinal Muscular Atrophy (SMA).
    Mix L; Schreiber-Katz O; Wurster CD; Uzelac Z; Platen S; Gipperich C; Ranxha G; Wieselmann G; Osmanovic A; Ludolph AC; Petri S; Lulé D
    Orphanet J Rare Dis; 2021 Jan; 16(1):10. PubMed ID: 33407722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene replacement therapy with onasemnogene abeparvovec in children with spinal muscular atrophy aged 24 months or younger and bodyweight up to 15 kg: an observational cohort study.
    Weiß C; Ziegler A; Becker LL; Johannsen J; Brennenstuhl H; Schreiber G; Flotats-Bastardas M; Stoltenburg C; Hartmann H; Illsinger S; Denecke J; Pechmann A; Müller-Felber W; Vill K; Blaschek A; Smitka M; van der Stam L; Weiss K; Winter B; Goldhahn K; Plecko B; Horber V; Bernert G; Husain RA; Rauscher C; Trollmann R; Garbade SF; Hahn A; von der Hagen M; Kaindl AM
    Lancet Child Adolesc Health; 2022 Jan; 6(1):17-27. PubMed ID: 34756190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug treatment for spinal muscular atrophy types II and III.
    Wadman RI; van der Pol WL; Bosboom WM; Asselman FL; van den Berg LH; Iannaccone ST; Vrancken AF
    Cochrane Database Syst Rev; 2020 Jan; 1(1):CD006282. PubMed ID: 32006461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of nusinersen in type 1, 2 and 3 spinal muscular atrophy: Real world data from Hungarian patients.
    Szabó L; Gergely A; Jakus R; Fogarasi A; Grosz Z; Molnár MJ; Andor I; Schulcz O; Goschler Á; Medveczky E; Czövek D; Herczegfalvi Á
    Eur J Paediatr Neurol; 2020 Jul; 27():37-42. PubMed ID: 32456992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Different trajectories in upper limb and gross motor function in spinal muscular atrophy.
    Coratti G; Pera MC; Montes J; Pasternak A; Scoto M; Baranello G; Messina S; Dunaway Young S; Glanzman AM; Duong T; De Sanctis R; Mazzone ES; Milev E; Rohwer A; Civitello M; Pane M; Antonaci L; Frongia AL; Sframeli M; Vita GL; DʼAmico A; Mizzoni I; Albamonte E; Darras BT; Bertini E; Sansone VA; Bovis F; Day J; Bruno C; Muntoni F; De Vivo DC; Finkel R; Mercuri E
    Muscle Nerve; 2021 Nov; 64(5):552-559. PubMed ID: 34327716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical, electrophysiological and molecular study of 26 chilean patients with spinal muscular atrophy].
    Castiglioni C; Levicán J; Rodillo E; Garmendia MA; Díaz A; Pizarro L; Contreras L
    Rev Med Chil; 2011 Feb; 139(2):197-204. PubMed ID: 21773657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study.
    Finkel RS; Chiriboga CA; Vajsar J; Day JW; Montes J; De Vivo DC; Yamashita M; Rigo F; Hung G; Schneider E; Norris DA; Xia S; Bennett CF; Bishop KM
    Lancet; 2016 Dec; 388(10063):3017-3026. PubMed ID: 27939059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spinal muscular atrophy functional composite score: A functional measure in spinal muscular atrophy.
    Montes J; Glanzman AM; Mazzone ES; Martens WB; Dunaway S; Pasternak A; Riley SO; Quigley J; Pandya S; De Vivo DC; Kaufmann P; Chiriboga CA; Finkel RS; Tennekoon GI; Darras BT; Pane M; Mercuri E; Mcdermott MP;
    Muscle Nerve; 2015 Dec; 52(6):942-7. PubMed ID: 25846132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of real-life outcome data of patients with spinal muscular atrophy treated with nusinersen in Switzerland.
    Tscherter A; Rüsch CT; Baumann D; Enzmann C; Hasselmann O; Jacquier D; Jung HH; Kruijshaar ME; Kuehni CE; Neuwirth C; Stettner GM; Klein A;
    Neuromuscul Disord; 2022 May; 32(5):399-409. PubMed ID: 35337708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autosomal dominant congenital spinal muscular atrophy: a true form of spinal muscular atrophy caused by early loss of anterior horn cells.
    Oates EC; Reddel S; Rodriguez ML; Gandolfo LC; Bahlo M; Hawke SH; Lamandé SR; Clarke NF; North KN
    Brain; 2012 Jun; 135(Pt 6):1714-23. PubMed ID: 22628388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fasudil improves survival and promotes skeletal muscle development in a mouse model of spinal muscular atrophy.
    Bowerman M; Murray LM; Boyer JG; Anderson CL; Kothary R
    BMC Med; 2012 Mar; 10():24. PubMed ID: 22397316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Six-Minute Walk Test demonstrates motor fatigue in spinal muscular atrophy.
    Montes J; McDermott MP; Martens WB; Dunaway S; Glanzman AM; Riley S; Quigley J; Montgomery MJ; Sproule D; Tawil R; Chung WK; Darras BT; De Vivo DC; Kaufmann P; Finkel RS;
    Neurology; 2010 Mar; 74(10):833-8. PubMed ID: 20211907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Upper limb module in non-ambulant patients with spinal muscular atrophy: 12 month changes.
    Sivo S; Mazzone E; Antonaci L; De Sanctis R; Fanelli L; Palermo C; Montes J; Pane M; Mercuri E
    Neuromuscul Disord; 2015 Mar; 25(3):212-5. PubMed ID: 25500010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nusinersen for Spinal Muscular Atrophy in the United States: Findings From a Retrospective Claims Database Analysis.
    Gauthier-Loiselle M; Cloutier M; Toro W; Patel A; Shi S; Davidson M; Bischof M; LaMarca N; Dabbous O
    Adv Ther; 2021 Dec; 38(12):5809-5828. PubMed ID: 34713391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.